BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) is a publicly traded the market company. As of May 21, 2026, BBOT trades at $9.12 with a market cap of $700.94M and a P/E ratio of -0.02. BBOT moved +0.92% today. Year to date, BBOT is -22.31%; over the trailing twelve months it is flat. Its 52-week range spans $7.60 to $14.87. Analyst consensus is strong buy with an average price target of $24.06. Rallies surfaces BBOT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for BBOT combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $9.12 |
| Market Cap | $700.94M |
| P/E Ratio | -0.02 |
| EPS | $-476.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.87 |
| 52-Week Low | $7.60 |
| Volume | 502 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.16K |
| Net Income | $-154.09M |
| Gross Margin | 0.00% |
8 analysts cover BBOT: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.06.